Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.54 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | WRN | Q14191 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600803 | 1.00 | NAAA (0.54) | NAAADGKAGAAHTTALDH1A1 | |
| SCHEMBL50301 | 0.89 | NAAA (0.64) | NAAADGKAGAAHTTALDH1A1 | |
| SCHEMBL4673456 | 0.86 | NAAA (0.47) | NAAADGKAGAAHTTALDH1A1 | |
| SCHEMBL4676648 | 0.86 | NAAA (0.47) | NAAADGKAGAAHTTALDH1A1 | |
| SCHEMBL27803412 | 0.86 | NAAA (0.69) | NAAADGKAHTTALDH1A1HPGD | |
| Water SCHEMBL28123302 | 0.86 | NAAA (0.61) | NAAADGKAGAAHTTALDH1A1 | |
| SCHEMBL4673337 | 0.84 | GAA (0.55) | NAAAGAAALDH1A1CYP1A2MGAM | |
| Ethylene SCHEMBL9937082 | 0.83 | NAAA (0.58) | NAAADGKAGAAHTTALDH1A1 | |
| Ethylene SCHEMBL6759867 | 0.83 | NAAA (0.58) | NAAADGKAGAAHTTALDH1A1 | |
| SCHEMBL28965374 | 0.83 | NAAA (0.44) | NAAADGKAGAAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163806-B2 | Controlled release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120010284-A1 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-8026285-B2 | Control release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076174-A1 | CONTROL RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, CTSA, ALG1 | NAAA 437/4885DGKA 3158/4885GAA 12/4885 |
| US-20120010284-A1 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, AADAC, LGMN | NAAA 497/4885DGKA 3147/4885GAA 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.